Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience
CM Schmidt, O Turrini, P Parikh, MG House… - Archives of …, 2010 - jamanetwork.com
Objective To determine the importance of hospital volume, surgeon experience, and surgeon
volume in performing pancreaticoduodenectomy (PD). Design, Setting, and Patients From …
volume in performing pancreaticoduodenectomy (PD). Design, Setting, and Patients From …
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma
…, C Loncle, E Calvo, O Turrini… - Proceedings of the …, 2013 - National Acad Sciences
Pancreatic ductal adenocarcinoma is one of the most intractable and fatal cancer. The
decreased blood vessel density displayed by this tumor not only favors its resistance to …
decreased blood vessel density displayed by this tumor not only favors its resistance to …
[HTML][HTML] Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
…, M Gilabert, M Bigonnet, S Garcia, O Turrini… - Nature …, 2018 - nature.com
Recent studies have offered ample insight into genome-wide expression patterns to define
pancreatic ductal adenocarcinoma (PDAC) subtypes, although there remains a lack of …
pancreatic ductal adenocarcinoma (PDAC) subtypes, although there remains a lack of …
[HTML][HTML] Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable …
Objectives This study aimed to determine the impact of a standardized pathological protocol
on resection margin status after pancreaticoduodenectomy (PD) for ductal adenocarcinoma. …
on resection margin status after pancreaticoduodenectomy (PD) for ductal adenocarcinoma. …
[PDF][PDF] Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts
…, L Marisa, C Loncle, O Gayet, V Moutardier, O Turrini… - Cell reports, 2017 - cell.com
Preclinical models based on patient-derived xenografts have remarkable specificity in
distinguishing transformed human tumor cells from non-transformed murine stromal cells …
distinguishing transformed human tumor cells from non-transformed murine stromal cells …
Genome profiling of pancreatic adenocarcinoma
…, F Viret, A Gonçalvès, O Turrini… - Genes …, 2011 - Wiley Online Library
Pancreatic adenocarcinoma is one of the most aggressive human cancers. It displays many
different chromosomal abnormalities and mutations. By using 244 K high‐resolution array‐…
different chromosomal abnormalities and mutations. By using 244 K high‐resolution array‐…
Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association …
Background Venous resection (VR) during pancreatectomy has been reported to neither
increase mortality nor morbidity and to provide similar survival outcomes in same stage tumors. …
increase mortality nor morbidity and to provide similar survival outcomes in same stage tumors. …
The learning curve for the laparoscopic approach to conservative mesorectal excision for rectal cancer: lessons drawn from a single institution's experience
T Bege, B Lelong, B Esterni, O Turrini… - Annals of …, 2010 - journals.lww.com
Objectives: We aimed to determine the most sensitive markers of the learning process for
laparoscopic conservative mesorectal excision (LCME) for rectal cancer to (1) generate a …
laparoscopic conservative mesorectal excision (LCME) for rectal cancer to (1) generate a …
Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study
Background The role of extended resections in the management of advanced pancreatic
neuroendocrine tumors (PNETs) is not well defined. Methods Between 1995 and 2012, 134 …
neuroendocrine tumors (PNETs) is not well defined. Methods Between 1995 and 2012, 134 …
[HTML][HTML] Prognostic value of PDL1 expression in pancreatic cancer
…, P Finetti, A Lopresti, M Gilabert, F Poizat, O Turrini… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the most aggressive human cancers. PD1/PDL1-inhibitors
recently showed promising results in different cancers with correlation between PDL1 tumor …
recently showed promising results in different cancers with correlation between PDL1 tumor …